Authors: Centeno C, Sheinkop M, Dodson E, Stemper I, Williams C, Hyzy M, Ichim T, Freeman M.
Published: 2018
Conclusion: The use of image-guided percutaneous BMC with platelet products yielded better results than exercise therapy as an effective alternative therapy for patients with symptomatic moderate to moderate-severe osteoarthritis of the knee.
Conclusion: In conclusion, both PRP and MSCs treatments were well tolerated, effective and safe to use. Repeated administrations and higher concentrations resulted in superior clinical improvements. A decrease in cartilage loss was observed in some MSCs trials. No severe adverse effects were documented. PRP treatment proved to be more efficacious among patients with KOA Kellgren-Lawrence (KL) grade I-II, while MSCs treatment proved to be more beneficial among the KOA KL grade II-III group.
Authors: Ip, H. L., Nath, D. K., Sawleh, S. H., Kabir, M. H., & Jahan, N.
Published: 2020
Conclusion: In conclusion, both PRP and MSCs treatments were well tolerated, effective and safe to use. Repeated administrations and higher concentrations resulted in superior clinical improvements. A decrease in cartilage loss was observed in some MSCs trials. No severe adverse effects were documented. PRP treatment proved to be more efficacious among patients with KOA Kellgren-Lawrence (KL) grade I-II, while MSCs treatment proved to be more beneficial among the KOA KL grade II-III group.
Author: George S. Themistocleous, George D. Chloros, Ioannis M. Kyrantzoulis, Ioannis A. Georgokostas, Marios S. Themistocleous, Panayiotis J. Papagelopoulos, Olga D. Savvidou,
Published: 2018
Conclusion: A single intra-articular injection of BMAC is a safe and reliable procedure that results in clinical improvement of knee OA.
Conclusion: This study shows that HA, ACS and BMAC intra-articular injections improve pain and symptoms of knee OA up to three months after treatment. However, BMAC is more effective than HA and ACS as it sustains symptom improvement for at least 12 months post treatment. In addition, BMAC is the most effective in the patients with more advanced knee OA.
Authors: Centeno, C., Pitts, J., Al-Sayegh, H., Freeman, M., & Centeno, C.
Published: 2015
Conclusion: Based on this small case series, the precise injection of autologous bone marrow-derived nucleated cells into the ACL ligament under fluoroscopic guidance, utilizing this specific protocol shows promise as a treatment for symptomatic grade 1, 2, and, possibly, nonretracted grade 3 ACL tears. Further investigation is warranted by these initial encouraging results. A well-populated randomized, controlled trial is needed to determine whether our results are repeatable and due to the intervention used in this study.
Authors: Wells, K., BA, Klein, M., MD, Hurwitz, N., BS, Santiago, K., BA, Cheng, J., PhD, Abutalib, Z., MHS, . . . Lutz, G.
Published: 2020
Conclusion: The cellular content of BMA samples varied widely between patients and was lower than the anticipated yield reported by the device's manufacturer. However, intra-articular BMA injections for knee OA in a small pilot cohort appeared to be safe with potential therapeutic value. Larger, prospective, double-blinded studies are warranted.
Authors: Gobbi, A., Scotti, C., Karnatzikos, G., Mudhigere, A., Castro, M., & Peretti, G. M.
Published: 2016
Conclusion: Treatment of cartilage lesions with BMAC and Hyalofast is a viable and effective option that is mainly affected by lesion size and number and not by age. In particular, it allows to address the >45 years population with functional outcomes that are comparable to younger patients at fnal follow-up
Authors: Dulic O, Rasovic P, Lalic I, Kecojevic V, Gavrilovic G, Abazovic D, Maric D, Miskulin M, Bumbasirevic M.
Published: 2021
Conclusion: Bone marrow aspirate concentrate, Leucocyte-Platelet Rich Plasma, and Hyaluronic acid injections are safe therapeutic options for knee OA and provide positive clinical out-comes after 12 months in comparison with findings preceding intervention. BMAC could be better in terms of clinical improvements in the treatment of knee OA than LR-PRP and HA up to 12 months. LR-PRP provides better outcomes than HA during the observation period, but these results are not statistically significant. More randomized controlled trials and high quality comparative studies are needed for direct correlative conclusions.
Conclusion: These results indicate a BMC knee injection has safety and efficacy and may be a reasonable non-surgical option for patients with moderate to severe knee OA.
Authors: Emadedin, M., Narges, L., Maede, L. G., Hosseini, S., Baharvand, H., & Aghdami, N.
Published: 2018
Conclusion: This randomized, triple-blind, placebo-controlled RCT demonstrated the safety and efficacy of a single intra-articular implantation of 40 × 10 autologous MSCs in patients with knee OA. Intra-articular implantation of MSCs provided significant and clinically relevant pain relief over 6 months versus placebo and could be considered a promising novel treatment for knee OA. We propose that further investigations should be conducted over an extended assessment period and with a larger cohort.
Authors: Chahla, J., Cinque, M. E., Schon, J. M., Liechti, D. J., Matheny, L. M., Laprade, R. F., & Clanton, T. O.
Published: 2016
Conclusion: This review denotes that there exists an overwhelming paucity of long-term data and high-level evidence supporting BMAC for the treatment of chondral defects. Nonetheless, the evidence available showed varying degrees of beneficial results of BMAC for the treatment of ankle cartilage defects. The limited literature presented in this review demonstrates the need for more advanced, comparative studies to further investigate the efficacy, safety and techniques for BMAC in the treatment of OLTs. The authors recommend that BMAC therapy should be performed with careful consideration until the application and target population for this treatment are established.
Authors: Hannon CP, Ross KA, Murawski CD, Deyer TW, Smyth NA, Hogan MV, Do HT, O'Malley MJ, Kennedy JG.
Published: 2015
Conclusion: BMS is an effective treatment strategy for treatment of OCLs of the talus and results in good medium-term functional outcomes. Arthroscopic BMS with cBMA also results in similar functional outcomes and improved border repair tissue integration, with less evidence of fissuring and fibrillation on MRI.
Authors: Houdek, M. T., Wyles, C. C., Collins, M. S., Howe, B. M., Terzic, A., Behfar, A., & Sierra, R. J.
Published: 2018
Conclusion: Conclusions Core hip decompression withi njection of concentrated bone marrow plus PRP improved pain and function; > 90% of hips in this series were without collapse at a minimum of 2 years. In this preliminary study,successful results were seen when nucleated cell count was high and modified Kerboul grade was low. Further randomized studies are needed to determine this procedure’s efficacy versus core decompression or nonoperative treatment alone.
Authors: Tomaru, Y., Yoshioka, T., Sugaya, H., Kumagai, H., Hyodo, K., Aoto, K., … Mishima, H.
Published: 2019
Conclusion: Both collapse and THA-conversion rates in the pre-collapse stage of ONFH were estimated at 49% (21/43) and 14%(6/43), respectively. The overall THA-conversionrate of ONFH was 34% (27/80). Based on our findings, the minimally-invasive and feasible CABMAT therapy can be considered as one of the alternatives for joint-preserving treatment of ONFH, especially in stages 1 and 2.
Authors: Houdek MT, Wyles CC, Collins MS, Howe BM, Terzic A, Behfar A, Sierra RJ.
Published: 2018
Conclusion: Core hip decompression with injection of concentrated bone marrow plus PRP improved pain and function; > 90% of hips in this series were without collapse at a minimum of 2 years. In this preliminary study, successful results were seen when nucleated cell count was high and modified Kerboul grade was low. Further randomized studies are needed to determine this procedure's efficacy versus core decompression or nonoperative treatment alone.
Authors: El-Kadiry, A., Lumbao, C., Rafei, M., Shammaa, R.
Published: 2021
Conclusion: Lumbar autologous BMAC injections safely and effectively reduced pain and opioid intake, ameliorated mobility, and induced parallel anatomical disc changes in spinal DJD-associated chronic LBP to a greater extent in IDD compared to facetogenic pain subgroups. These data further exhibit the clinical utility of BMAC, which may prove to be a substitute for IDD surgery following wider-scale studies.
Authors: Navani, A., MD, Ambach, M. A., MD, Navani, R., MS, & Wei, J., DO
Published: 2018
Conclusion: Intradiscal PRP and BMC injections are promising treatments in patients with discogenic chronic low back and leg pain. When combining proper technique with best known evidence-based practice, this treatment appears to demonstrate good efficacy and safety profile. There are several advantages to the use of autologous biologics: they are readily available, simple to use, cost effective, natural, and potentially healing in nature. While the preliminary results with this therapy have been promising, further well-designed randomized controlled studies are warranted in order to understand the full breadth of its efficacy, risks, applications and complications.
Authors: Pettine, K. A., Suzuki, R. K., Sand, T. T., & Murphy, M. B.
Published: 2017
Conclusion: There were no adverse events related to marrow aspiration or injection, and this study provides evidence of safety and feasibility of intradiscal BMC therapy. Patient improvement and satisfaction with this surgical alternative supports further study of the therapy.
Conclusion: Osteoarthritis is a progressive and degenerative condition. With an aging population it promises to remain a significant cause of pain and disability. Whilst osteoarthritis is an active, inflammatory and progressive condition, there has been no development of disease modifying pharmaceutical therapies. Indeed, all currently accepted therapies are aimed at symptom control rather than disease prevention. Current conservative management strategies fail to alter disease progression and surgical management in the form of joint replacement is associated with not insignificant complications.
Authors: Cavallo, C., Boffa, A., Andriolo, L. et al.
Published: 2021
Conclusion: There is a growing interest in the field of BMAC injections for the treatment of OA, with promising results in preclinical and clinical studies in terms of safety and effectiveness. Nevertheless, the current knowledge is still preliminary. Preclinical research is still needed to optimize BMAC use, as well as high-level large controlled trials to better understand the real potential of BMAC injections for the treatment of patients affected by OA.
Conclusion: The single-insertion method produced final cellular concentrations and culture results that were not significantly different from those of a multiple-insertion method. Additionally, the single-insertion site technique was significantly less painful to the patient at the time of the procedure as well as 24 hours after aspiration.
Conclusion: In conclusion, MSCs within BMAC have the self-renewal capacity, can undertake clonal expansion, and differentiate into various mesodermal tissues. MSCs are also a rich source of several growth factors and cytokines, which have a paracrine and immunomodulatory effect. For this reason, BMAC has emerged as a promising biologic tool for regenerative medicine. Studies published to date have reported relatively favorable outcomes, but most of them have focused on clinical improvement rather than quality of regeneration. Moreover, heterogeneity between the studies may not allow for direct comparison.
Authors: Gendron N, Zia Chahabi S, Poenou G, Rivet N, Belleville-Rolland T, Lemaire P, Escuret A, Ciaudo M, Curis E, Gaussem P, Siguret V, Darnige L.
Published: 2019
Conclusion: Our study suggests that for BMA from any site, the patient needs to be reassured and well informed regarding the procedure in an attempt at the lowering pain level experienced. For BMA from the sternal site, we recommend the use of lidocaine infiltration. Additional procedures like hypnosis or music therapy could improve the psychological management of the pro-cedure and remain to be investigated [19].
Authors: Masoudi E, Ribas J, Kaushik G, Leijten J, Khademhosseini A.
Published: 2016
Conclusion: Blood derivatives, and in particular PRP, represent a promising source to provide a natural cocktail of autologous growth factors that potentiate stem cell proliferation, migration, and differentiation. Moreover, clinical trials have confirmed PRP’s safety as well as its ability to improve the clinical outcomes of stem cell based therapies. However, gaining control over blood derivatives chemical composition remains key to achieving reproducible and predictable clinical results.
